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Table l shows that D-Di values were not statistically different be-
tween groups I, II and healthy subjects without thrombotic antecedents.
Two patients in group I had D-Di above the critical cut-off of 500
ng/ml. One displayed a borderline value at 540 ng/ral. The other had
had several episodes of DVT, the latest 6 months before, at the age of
67 years. Vena cava Interruption was performed on this occasion. Her D-
Di value was 850 ng/ml. It has been demonstrated that normal values of
D-Di increase with age ( l ) . Critical cut-off is probably higher in the el-
derly and this value might be considered äs normal for the patient's age.
Alternatively, this might be an effect of the vena cava filter, although
another patient with a filter in group I displayed a low D-Di value.
We previously found that, 3 months after a DVT, D-Di levels re-
turned to the normal ränge established in an age-matched control popula-
tion, when the patients were correctly treated by oral anticoagulants (2).
Although that study and the present one were not performed in the
same patients, these results suggest that once D-Di level has returned to
its baseline value, within 3 months after the acute episode, it remains
stable and low after the anticoagulant treatment is stopped.
Measurement of D-Di is therefore of potential value for the diagno-
sis of recurrent DVT. This conclusion is restricted to the patient popu-
lation of this study, i.e. young patients without Symptoms of post-phle-
bitic syndrome, associated disease, or inherited disorder predisposing
to thrombosis.
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High Titer Inhibitors in Severe Haemophilia A
A Meta-analysis Based on Eight Long-term Follow-up Studies concerning Inhibitors
Associated with Crude or Intermediate Purity Factor VIII Products
Sir,
The recent introduction of factor VIII products produced by recom-
binant DNA technology for the treatment of patients with hemophilia A
has rekindled the interest in the occurrence of anti-factor VIII antibo-
dies (l, 2). Specific patient characteristics may be associated with a
high risk of inhibitor formation, e.g., gene deletions. Additionally,
some products cause more Inhibitors than others, possibly due to neoanti-
gens induced by the production process (3, 4). Utffortonately, there is
insufficient Information in the literature that might be used äs a histori-
cal yardstick for the cornparison of inhibitor incidences associated with
older generations of products. Plasma derived factor VIII, purified
using monoclonal antibodies, could serve äs a suitable cornparison for
the recombinant products but the two published prospective studies on
these products are very small and were not specifically designed for in-
hibitor surveillance (5, 6). New studies on these products in previously
untreated patients are ongoing. There are eight long-term follow-up stu-
dies from single haemophilia centers or groups of centers that can pro-
vide useful Information on crade and intermediate purity products
(7-14). In each of these studies, all patients were followed from birth by
inhibitor measurements at regulär outpatient visits. However, their
cornparison is hampered by differences in the study designs.
The authors of the eight studies have collaborated to produce one set
of consistent data and to provide useful Information on the risk of high
response type inhibitors in patients with severe haemophilia. By re-
stricting the analysis to severe haemophilia (defined äs <1% factor VIII
in all studies) we focussed on those patients with the highest risk. In this
way we avoided the inclusion of patients with very little exposure to
factor VIII, since virtually all patients with severe haemophilia have
had a sizable numer of exposures by the age of five years. Unfortunate-
ly, we could not use the number of exposure days for the time axis,
since this Information was not available for several of the studies. The
restriction to high response type inhibitors served to concentrate on in-
hibitors that are clinically significant. For three studies "high response"
was defined äs a maximum inhibitor titer in excess of ten Bethesda
units (8,10,11) and in five it was defined äs in excess of five Bethesda
units (7, 9,12-14). The authors combined the raw data from their stu-
dies and this allowed us to calculate a cumulative incidence for the to-
tal group of 451 patients. The cumulative incidence curves for the indi-
vidual studies are shown in Fig. l a and the curve for the combined set
of data in Fig. Ib. At the age of three years the cumulative incidence
was 10 percent (95 percent confidence interval: 7 to 13 percent) and
this gradually increased to 20 percent at age 18.
Although we eliminated two major differences by restricting the
analysis to severe haemophilia and high response type inhibitors it is
clear that some differences remain that may have contributed to the
widely varying results. First, transiency of the inhibitors was reported
rather frequently for studies 3 (9) and 8 (14), which may have led to
higher incidences than in the other studies. Second, in study 7 (13)
only cryoprecipitate was used and similarly, all inhibitors found in
study 2 (8) occurred during the period that all patients exclusively used
cryoprecipitate. Apparently, the very low inhibitor incidence in study 7
cannot be ascribed solely to the use of this crude product. Third, the in-
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Table l The cumulative inhibitor incidence at the plateau phase related to the
intensity of factor VIII replacement*
au -
40-
30-
20-
10-
3
J
8
4
 1 2
', \ ,
; .-Γ---1"' 5
;--· i ;
--' J ; 7l
0 2 4 β 8 10 12 14 16 18 20 22 24 26 28 30
years of follow-up
Study number Cumulative incidence plateau
(%)
7 2
5 7
6 19
2 20
1 21
4 21
8 25
3 46
Annual factor VIII dose
U/kg/year
1400-2000
>2000
200-800
200 - 800
200-800
200 - 800
200 - 800
800 - 1400
*The authors were asked to indicate their usual annual factor VIII dose per kg
bodyweight: <200, 200 - 800, 800 - 1400, 1400 - 2000, or >2000 Units per kg
per year.
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Fig. l The cumulative incidence with 95% confidence intervals of high
response type factor VIII inhibitors in severe haemophiliaA based on the
data from the eight follow-up studies (individual data panel A, combined data
panelB). Study l = ref 7, study2 = ref 8, study 3 = ref 9, study4 = ref 10,
study 5 = ref 11, study 6 = ref 12, study 7 = ref 13, study 8 = ref 14
tensity of factor VIII replacement was different. In Table l, the inten-
sity of replacement is shown next to the height of the plateau of the
cumulative incidence curves. It appears that the intensity of replace-
ment is not an exclusive determinant of the inhibitor incidence. Finally,
except for studies 7 and 2, most patients from raost centers used more
man one product. If neo-antigens in the products play a role, every
switch from one product to another may be associated with additional
risk for inhibitor formation.
The fmdings of this study show that one needs many years of expo-
sure before a plateau is reached. Consequently, prospective studies with
new products require long follow-up. In addition, the wide confidence
interval around the curve for the combined data suggests that it will
require prohibitively large numbers of patients to prove that a new
product is safer or less safe than the older products. For this reason we
have proposed (15) that national or international pharmacovigilance
programmes be undertaken for this purpose. Furthermore, for future
studies we recommend to do separate analyses for patients with haemo-
philia of different severities, to use exposure days for the time axis and
to concentrate on clinically relevant inhibitors. Consensus should be
sought for the defmition of "clinically relevant". As a minimum this
term should imply criteria for inhibitor titer and persistence of the inhi-
bitor, but possibly other aspects äs well.
E. Briet and F. R. Rosendaal, Leiden, The Netherlands; W. Kreuz, Frank-
furt, Germany; V. Rasi, Helsinki, Finland; K. Peerlinck and J. Vermylen, Leu-
ven, Belgium; R. Ljung, Malmö, Sweden; A. Rocino, Naples, Italy; J. Addiego,
Oakland, CA, USA; J. I. Lorenzo, Valencia, Spain; I. Pabinger, Vienna, Austria
Correspondence to: Dr. Ernest Briet, Haemostasis and Thrombosis Re-
search Centre, Department of Haematology, University Hospital, building l,
C2-R, p. o. box 9600, N-2300 RC, Leiden, The Netherlands - FAX Number:
+ 3171225555
References
1. Lusher JM, Arkin S, Abildgaard CF, Schwanz RS, and the Kogenate Pre-
viously Untreated Patient Group. Recombinant factor VIII for the treatment
of previously untreated patients with hemophilia A - Safety, efficacy, and
development of inhibitors. N Eng! J Med 1993; 328: 453-9.
2. Bray GL, Courter SG, Lynes M, Lee M, Gomperts E, and the Recombi-
nate Study Group. Safety, efficacy and inhibitor risk of recombinant factor
VIII (Recombinate) in a cohort of previously untreated patients (PUP's)
with severe hemophilia. Thromb Haemost 1993; 69: 1205 (Abstract).
3. Peerlinck K, Arnout J, Gilles JG, Saint-Remy J-M, Vermylen J. A higher
than expected incidence of factor VIII inhibitors in multitransfused haemo-
philia A patients treated with an intermediate purity pasteurized factor VIII
concentrate. Thromb Haemost 1993; 69:115-8.
4. Rosendaal FR; Nieuwenhuis HK, Van den Berg HM et al. A sudden in-
crease in factor VIII inhibitor development in multitransfused hemophilia
A patients in The Netherlands, Blood 1993; 81: 2180-2186.
6. Lusher JM, Salzman PM, Monoclate study group. Viral safety and inhibitor
development associated with factor VIIIC ultra-purified from plasma in he-
mophiliacs previously unexposed to factor VIIIC concentrates. Semin He-
matol 1990; 27 Suppl 2:1-7.
6. Addiego JE Jr, Gomperts E, Liu S-L et al. Treatment of hemophilia A with
a highly purified factor VIII concentrate prepared by anti-FVIIIC immuno-
affinity chromatography. Thromb Haemost 1992; 67:19-27.
7. Schwarzinger I, Pabinger I, Korninger C et al. Incidence of inhibitors in pa-
tients with severe and moderate hemophilia A treated with factor VIII con-
centrates. Am J Hematol 1987; 24: 241-5.
8. Rasi V, Ikkala E. Haemophiliacs with factor VIII inhibitors in Finland:
prevalence, incidence and outcome. Br J Haematol 1990; 76: 369-71.
9. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor
VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
10. Lorenzo JI, Garcia R, Molina R. Factor VIII and factor IX inhibitors in
haemophiliacs (Letter to the Editor). Lancet 1992; 339: 1550-1.
163
,4*
11. Ljung R, Petrini P, Lindgren A-C, Tengborn L, Nilsson IM. Factor VIII and
factor IX Inhibitors in haemophiliacs (Letter to the Editor). Lancet 1992;
339:1550.
12. De Biasi R, Rocino A, Papa ML, Salerno E. Incidence of inhibitors in he-
mophilia A patients Thromb Haemost 1993; 69:1103 (Abstract).
13. Peerlinck K, Rosendaal FR, Vermylen J. Incidence of inhibitor develop-
ment in a group of young hemophilia A patients treated exclusively with
lyophilized cryoprecipitate. Blood 1993; 81: 3332-5.
14. Addiego JE, Kasper CK, Abildgaard C et al. Frequency of inhibitor devel-
opment in haemophiliacs treated with low purity factor VIII. Lancet 1993;
342: 462-4.
15. Vermylen J, Briet E. Factor VIII preparations: Need for prospective phar-
macovigilance. Lancet 1993; 342: 693-4.
Received January 31,1994 Accepted after revision March 15,1994
handled by J. Arnout
Endothelial Cell Markers (vWF, t-PA and PAH) in the Elderly
Dear Sir,
Within the frame of a study intended to determine fibrinolytic para-
meters in an eider population, we have studied a group of 47 patients
strictly comparable for age and sex ratio to a control group of 26 sub-
jects. Various disease processes commonly found in the elderly were
documented in the group of patients (Table 1). Control of eider sub-
jects had no evolutive pathology äs suggested by a normal clinical
examination, C reactive protein (CRP) levels below 10 g/l and normal
coagulation routine tests. The parameters studied were compared to
those obtained in a younger control group (<60 years old, n = 20).
In a preliminary communication (1) we reported the levels of pro-
urokinase (scu-PA) antigen and activity levels in a geriatric population.
Scu-PA antigen was quantified with a double sandwich ELISA, äs de-
scribed (2); scu-PA activity was measured using a Βίο Immuno Assay
in which the scu-PA bound to a first antibody was activated with plas-
min and then colorimetrically measured (3). No significant differences
were found between controls and patients (Table 1) nor between our
geriatric healthy population and the younger control group (3.6 ±
0.9 ng/ml, mean ± SD versus 3.5 ± 1.1 ng/ml for scu-PA antigen; 2.36 ±
0.6 ng/ml versus 2.1 ± 0.4 ng/ml for scu-PA activity). However, in five
patients (acute myeloid leukemia, n = 1; severe liver failure, n = 2;
and metastatic neoplasia, n = 3), an abnormal high level of scu-PA anti-
gen and activity was documented.
This work has been presently extended to the determination of von
Willebrand factor (vWF), tissue plasminogen activator (t-PA), and its
inhibitor (PAI-1) measured with ELISA assays (resftectively Assera-
chrom vWF, t-PA and PAI from Diagnostica Stago, Asnieres, France).
Acute phase reactant proteins (fibrinogen, CRP) were also deter-
mined in both geriatric subjects and in a younger control group
(<60 years).
A statistical significant difference (p <0.01, Mann and Whitney test)
between eider controls and patients for CRP and fibrjnogen levels (Ta-
ble 1) was suggestive of a chronic inflammatory state in the patient
group; patients also had increased vWF levels (1.97 ± 0.84 u/ml versus
1.62 ± 0.59 u/ml for controls, p = 0.03) which were strongly correlated
with CRP (p <0.01). As previously reported by other groups (4), vWF
levels were higher in the elderly (vWF antigen level for the younger
control group was 1.0 ± 0.33 u/ml, mean ± SD).
The levels of t-PA and PAI-1 were comparable in the eider healthy
and ill groups (Table 1). In agreement with a previous report (5), t-PA
levels were higher in the geriatric population (13 ± 9.7 ng/ml, mean ±
SD) äs compared to those (5.5 ± 3 ng/ml) of a younger control group
(<60 years). A concomitant increase in PAI-1 (35.7 ± 26 ng/ml versus
16.4 ± 11.9 ng/ml, mean ± SD for the younger healthy group) was ob-
served and was shown to be significantly correlated with t-PA levels
(p = 0.01) and to the CRP, i.e., the inflammatory state of the patients
(p = 0.01).
In control older subjects, proteins synthetized by the vascular endo-
thelium, vWF and PAI-1, were shown to be increased whereas CRP
and fibrinogen, synthetized by the liver remained within the normal
ränge, thus suggesting chronic Stimulation of the endothelium. The well
known increase in the plasma level of t-PA antigen is probably related
to the same phenomenon although a decrease in the hepatic clearance of
t-PA may also be evoked.
Finally, no correlation was found between the levels of scu-PA and
the following parameters: CRP, vWF antigen, t-PA and PAI-1 antigens
and serum creatinine level.
Table l
Controls
Patients t
p value*
N
ratio
M/F
26
(7/19)
47
(13/34)
Age
(years)
mean ± SD
81±8
82±7
scu-PA Ag
(ng/ml)
mean ± SD (ränge)
3.6 ±0.9
(2.2-5.8)
5.4 ±8.1
(1.6-56.1)
NS
t-PA Ag
(ng/ml)
median (ränge)
11.8
(3.8-46)
10
(3.5-46)
NS
PAI-1 Ag
(ng/ml)
median (ränge)
27.5
(9.5 - 100)
24
(6.5 - 120)
NS
CRP
(g/l)
median (ränge)
5
(5-10)
13
(5-246)
<0.01
vWFAg
(u/ml)
mean ± SD
1.62 ±0.59
1.97 ±0.84
<0.05
Fibrinogen
(BÄ)
mean ± SD
3.7 ±0.9
4.6 ±1.6
<0.01
NS: non significant
*: Mann-Whitney test. ivi mi  vy muii^ itui
T: with the following pathology: iron, folic acid and vitamin B12 deficiencies (n = 7), chronic lymphocytic leukemia and lymphoma (n = 5), acute myeloid
leukemia (n = 1), cerebral or peripheral vascular ischaemia (n = 9), digestive tract neoplasia (n = 9), diabetes (n = 1), various inflammatory reactions (n = 3),
bacterial infections (n = 2) and renal (n = 5), pulmonary (n = 3) or liver (n = 2) disease.
